The higher immunoreactivity to ACE (angiotensin converting enzyme) in patients with type 2 diabetes mellitus than in non-diabetic individuals

Endocr J. 2003 Apr;50(2):209-13. doi: 10.1507/endocrj.50.209.

Abstract

In a random sample of 200 patients with type 2 diabetes mellitus, immunoreactivities to ACE (angiotensin converting enzyme) were measured by ELISA. Immunoreactivities were positive for 129 (64.5%) patients, and were positive in 30 (83.3%) out of 36 patients in the early stage of clinical diabetic nephropathy. Serum ACE activity in rabbits immunized with ACE decreased to 50% of the control level after 7 months (78.0 +/- 3.8 IU/L/37 degrees C, basal, 42.0 +/- 5.0 at 7 months and 33.3 +/- 3.5 IU/L/37 degrees C at 8 months, respectively). When rabbit serum containing antiACE antibodies was mixed, after heat-treatment at 56 degrees C for 30 min, with normal human serum, the ACE activity was reduced in a concentration-dependent manner. These results suggested that anti-ACE autoantibody may be present in patients with type 2 diabetes mellitus. However, the absence of data on the epitope for the antibody does not allow any conclusion except that the immunoreactivities to ACE are higher in type 2 diabetic patients than in non-diabetic individuals.

MeSH terms

  • Adult
  • Animals
  • Antibodies / blood
  • Case-Control Studies
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / enzymology*
  • Diabetic Nephropathies / enzymology
  • Diabetic Nephropathies / etiology
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Male
  • Middle Aged
  • Peptidyl-Dipeptidase A / blood
  • Peptidyl-Dipeptidase A / immunology
  • Peptidyl-Dipeptidase A / metabolism*
  • Rabbits

Substances

  • Antibodies
  • Peptidyl-Dipeptidase A